Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Grier received his MD from the University of Pennsylvania in 1976, and then trained in pediatrics, internal medicine, and infectious disease at the University of North Carolina. He joined Dana-Farber Cancer Institute in 1984. He is a past president of the American Society of Pediatric Hematology/Oncology and is a member of the steering committee for Bone Tumors in the Children's Oncology Group.
At the Children's Oncology Group, we work on the design and implementation of studies regarding Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. The Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries. Dr. Grier is an active member of the Bone Tumor Disease Committee and the Soft Tissue Sarcoma Committee of this group. As part of the Pediatric Solid Tumor Center at Dana-Farber/Boston Children's, we help organize laboratory and clinical cross talk. We are also involved in cancer survivor studies that focus on the late effects of chemotherapy. These studies are led by Dr. Lisa Diller at the David B. Perini Jr. Quality of Life Clinic at Dana-Farber Cancer Institute. In addition, we participate in a study of the best application of palliative care through our work with the Pediatric Advanced Care Team, led by Dr. Joanne Wolfe.
Dana-Farber Cancer Institute450 Brookline AvenueDana G350Boston, MA 02215Get Directions